BidaskClub lowered shares of Entellus Medical, Inc. (NASDAQ:ENTL) from a strong-buy rating to a buy rating in a report released on Tuesday.

A number of other research firms also recently commented on ENTL. Piper Jaffray Companies reaffirmed a buy rating on shares of Entellus Medical in a research report on Wednesday, July 12th. Zacks Investment Research downgraded shares of Entellus Medical from a hold rating to a sell rating in a research report on Tuesday, July 11th. Canaccord Genuity downgraded shares of Entellus Medical from a buy rating to a hold rating and cut their target price for the stock from $22.00 to $18.00 in a research report on Thursday, May 4th. ValuEngine raised shares of Entellus Medical from a strong sell rating to a sell rating in a research report on Friday, June 2nd. Finally, William Blair reiterated an outperform rating on shares of Entellus Medical in a research note on Wednesday, May 10th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. Entellus Medical presently has an average rating of Hold and an average price target of $21.83.

Entellus Medical (ENTL) traded down 0.29% during trading on Tuesday, reaching $17.38. The company had a trading volume of 68,537 shares. The firm’s market capitalization is $380.90 million. The firm’s 50 day moving average price is $16.11 and its 200 day moving average price is $15.14. Entellus Medical has a 12-month low of $11.47 and a 12-month high of $22.63.

Entellus Medical (NASDAQ:ENTL) last posted its earnings results on Wednesday, May 3rd. The medical technology company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.04. Entellus Medical had a negative net margin of 39.02% and a negative return on equity of 60.56%. The business had revenue of $19.11 million during the quarter, compared to the consensus estimate of $19.61 million. During the same quarter in the previous year, the firm posted ($0.37) EPS. The firm’s revenue was up 13.0% on a year-over-year basis. Equities research analysts forecast that Entellus Medical will post ($1.35) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/bidaskclub-downgrades-entellus-medical-inc-entl-to-buy/1461552.html.

In other Entellus Medical news, CFO Brent Moen purchased 6,100 shares of the company’s stock in a transaction dated Monday, May 8th. The shares were acquired at an average price of $12.21 per share, for a total transaction of $74,481.00. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Robert S. White purchased 10,000 shares of the company’s stock in a transaction dated Monday, May 8th. The shares were acquired at an average price of $12.24 per share, for a total transaction of $122,400.00. The disclosure for this purchase can be found here. Insiders have bought a total of 17,700 shares of company stock worth $216,625 in the last quarter. Corporate insiders own 9.10% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE boosted its position in Entellus Medical by 53.8% in the first quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock worth $102,000 after buying an additional 2,594 shares during the period. Parametric Portfolio Associates LLC boosted its position in Entellus Medical by 5.6% in the first quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock worth $150,000 after buying an additional 573 shares during the period. Swiss National Bank boosted its position in Entellus Medical by 98.9% in the first quarter. Swiss National Bank now owns 17,700 shares of the medical technology company’s stock worth $244,000 after buying an additional 8,800 shares during the period. TD Asset Management Inc. purchased a new position in Entellus Medical during the first quarter worth $279,000. Finally, Citadel Advisors LLC purchased a new position in Entellus Medical during the first quarter worth $290,000. Institutional investors and hedge funds own 75.81% of the company’s stock.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Analyst Recommendations for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.